FILING ANALYSIS · THURSDAY, NOVEMBER 5
Entrada Therapeutics, Inc. TRDA — 8-K: Results of Operations and Financial Condition
neutral
Entrada Therapeutics reported its Q3 2026 financial results, with $193 million in cash and cash equivalents, and announced several clinical trial updates, including the expected release of ELEVATE-44-201 Cohort 1 data by year-end 2026 and Cohort 2 data in Q1 2027, but no quantified surprises were disclosed
How we read impact: we grade every directional call in the open. Impact labels are AI estimates — not investment advice. See the full disclaimer.
Get filings like this every market day
The US SEC filings, UK RNS, EU notices, and Polymarket odds that matter — scored by AI, in one email.
Subscribe free →